[ET Net News Agency, 2 January 2020] CSPC Pharmaceutical Group Limited (01093) said
"Sunitinib Malate Capsules (12.5mg)" developed by CSPC Ouyi Pharmaceutical Co., Ltd., a
subsidiary of the company, has been granted drug registration approval by the National
Medical Products Administration of the People's Republic of China, being the first generic
drug of this type approved in China.
Sunitinib Malate is an oncology drug indicated for the treatment of 1) inoperable
advanced renal cell carcinoma (RCC); 2) gastrointestinal stromal tumour (GIST) after
failure of or intolerance to imatinib mesylate treatment; and 3) progressive,
well-differentiated pancreatic neuroendocrine tumour (pNET) in adult patients with
unresectable or metastatic disease. (RC)